Cambridge Bioscience Limited

Cambridge Bioscience Limited is a key player in the life sciences sector, specializing in high-quality research products and services for biotechnology and pharmaceutical industries, ensuring precision and reliability in scientific research. Founded in 1984, Cambridge Bioscience Limited focuses on distributing life science research products to institutions and companies. The company headquarters is located in Cambridge, UK, serving a global clientele. The founder has an extensive background, having previously established other enterprises in the bioscience field, although specific names are not disclosed.

The firm has undergone strategic pivots to better align with market needs, enhancing its product offerings and service capabilities to fit evolving research demands. Cambridge Bioscience specializes in the distribution of a wide range of high-quality life science research products, including antibodies, assays and ELISAs, biochemicals, blood products, cDNA clones, cell lines, and molecular biology tools. These products cater to the needs of research institutions, biotechnology firms, and pharmaceutical companies, supporting applications in drug discovery, diagnostics, and cell biology. The company serves markets in Europe, North America, and Asia-Pacific while adhering to stringent quality standards to ensure reliable efficacy for researchers.

Cambridge Bioscience generates revenue primarily through direct sales to research institutions and companies in the life sciences sector. Transactions are facilitated through online purchases, telephone orders, and procurement systems, tailored to accommodate the needs of their clientele. The pricing for products varies by category, with flagship items commanding premium pricing due to their demand and quality. Their business-to-business revenue model focuses on meeting the technical requirements of professional users in diverse research environments.

Cambridge Bioscience Limited aims to enhance its product line with new offerings in the coming year, designed to support various cutting-edge research initiatives. The company plans to expand into emerging markets in Asia and South America by 2025, leveraging its established distribution channels to increase its global footprint. Recent funding will be utilized to support these initiatives, focusing on product development and market entry strategies.